New hope for taming deadly CAR-T side effect
NCT ID NCT07424222
Summary
This early study is testing if a pill called ruxolitinib can safely treat a severe, life-threatening immune system overreaction that sometimes happens after CAR-T cell therapy for cancer. The study will enroll about 16 adults who develop this condition, called IEC-HS, to see if the drug helps control it. Participants will take the pill twice daily for up to 8 weeks while doctors closely monitor their response and safety.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNE EFFECTOR ASSOCIATED HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS-LIKE SYNDROME (IEC-HS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.